Enbrel market seen reaching $22 billion by 2030

The global Enbrel market is projected to grow from $16.8 billion in 2025 to $17.8 billion in 2026, then reach $22.1 billion by 2030, according to The Business Research Company. The report points to rising autoimmune disease prevalence, biosimilar competition and broader biologic use as the main forces shaping demand.

Why it matters: - The Enbrel market is tied to the growing burden of autoimmune disease, which is increasing demand for biologic therapies that can reduce inflammation and prevent tissue damage. - The forecast signals continued spending on etanercept-based treatment even as biosimilars put pressure on branded biologics. - Regional growth patterns show where providers, distributors and drug makers may find the strongest demand over the next several years.

What happened: - The Business Research Company published The Business Research Company’s Enbrel Market Research Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report values the Enbrel market at $16,825.42 million in 2025 and projects $17,802.88 million in 2026. - The report forecasts the market will reach $22,054.02 million by 2030. - The report estimates a 5.8% CAGR from 2025 to 2026 and a 5.5% CAGR through 2030. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to grow fastest during the forecast period.

The details: - Enbrel is the brand name for etanercept, a prescription biologic used to treat autoimmune disorders. - Enbrel blocks tumor necrosis factor, or TNF, a protein involved in inflammation. - The drug is used for conditions including rheumatoid arthritis and psoriasis. - The market growth outlook is supported by the rising prevalence of autoimmune diseases, the clinical effectiveness of TNF inhibitors and wider use of biologics in rheumatology. - Established reimbursement systems for biologics and growing physician familiarity with etanercept-based therapies are also supporting demand. - The forecast period reflects stronger competition from biosimilars, more demand for cost-effective biologic options and expansion in specialty pharmacy distribution. - The report also cites innovation in biologic formulations, wider use of patient-friendly delivery methods, more chronic autoimmune disease management and improved cold-chain distribution as market trends. - The analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The report cites Arthritis Australia data from February 2024 showing that about 562,378 Australians are expected to be living with rheumatoid arthritis by 2025, equal to 14% of the total arthritis population. - The company says the report is available with a free sample and a full report download. - The source includes links for a free sample of the report and the full report.

Between the lines: - The market outlook suggests Enbrel remains commercially relevant, but growth is likely to become more dependent on pricing, access and distribution efficiency as biosimilars expand. - North America’s lead points to a mature market with established reimbursement and prescribing patterns. - Faster growth in Asia-Pacific suggests the next phase of expansion may come from broader diagnosis, treatment access and awareness rather than from saturated Western markets.

What's next: - The market will likely be shaped by how quickly biosimilars gain traction and how manufacturers respond with delivery and formulation improvements. - Expansion in emerging regions could become a bigger growth driver if healthcare access and autoimmune disease awareness continue to rise. - Specialty pharmacy channels and cold-chain logistics are likely to matter more as biologic distribution expands. - The report’s 2030 forecast gives investors and drug makers a benchmark for planning in a more competitive biologics market.